---
layout: post
title: "Revocation of Authorization of Emergency Use of an In Vitro Diagnostic Device for Detection and/or Diagnosis of COVID-19; Availability"
date: 2026-02-05 18:59:15 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-11122
original_published: 2022-05-24 00:00:00 +0000
significance: 8.00
---

# Revocation of Authorization of Emergency Use of an In Vitro Diagnostic Device for Detection and/or Diagnosis of COVID-19; Availability

**Published:** February 05, 2026 18:59 UTC
**Source:** Federal Register
**Original Published:** May 24, 2022 00:00 UTC
**Document Number:** 2022-11122

## Summary

The Food and Drug Administration (FDA) is announcing the revocation of the Emergency Use Authorization (EUA) (the Authorization) issued to Clinical Research Sequencing Platform (CRSP), LLC at the Broad Institute of MIT and Harvard (Broad Institute) for the CRSP SARS- CoV-2 Real-time Reverse Transcriptase (RT)-PCR Diagnostic Assay. FDA revoked this Authorization under the Federal Food, Drug, and Cosmetic Act (FD&C Act). The revocation, which includes an explanation of the reasons for revocation, is reprinted in this document.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/05/24/2022-11122/revocation-of-authorization-of-emergency-use-of-an-in-vitro-diagnostic-device-for-detection-andor)
- API: https://www.federalregister.gov/api/v1/documents/2022-11122

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
